HIV Antivirals Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

HIV Antivirals DMPK and Bioanalytical Services

HIV antiviral bioanalysis is rarely a single-drug problem. Research workflows may involve nucleoside analogs with limited metabolism, CYP-metabolized NNRTIs, UGT-cleared integrase inhibitors, renal-excretion-dominant compounds, and multi-drug regimen panels that must remain selective across unrelated chemistries.

Creative Proteomics develops LC-MS/MS and DMPK workflows for HIV antivirals, including parent-drug bioanalysis, MetID, CYP / UGT metabolism support, hepatocyte and microsome model analysis, renal-excretion profiling, DDI-oriented assays, and custom antiretroviral panels.

Browse HIV Antiviral Drug Index Request Custom HIV Antiviral Method Support

Regimen panelsResolve NRTIs, NNRTIs, integrase inhibitors, and companion analytes in one study-aware method.

CYP / UGT splitSeparate Phase I NNRTI metabolism from UGT-driven Phase II integrase inhibitor workflows.

Minimal-metabolism NRTIsPrioritize distribution, renal excretion, and parent-drug exposure when MetID is not the main driver.

HIV Antiviral Workflow Risks DMPK Strategy Map

🧩

Regimen-level analyte designHIV studies often require panels across unrelated antiretroviral chemistries and concentration ranges.

⚙

CYP and UGT metabolismEfavirenz, nevirapine, rilpivirine, zidovudine, dolutegravir, and raltegravir require different enzyme logic.

🧪

Minimal metabolism vs MetIDLamivudine, emtricitabine, and tenofovir need exposure-ready bioanalysis rather than broad metabolite discovery.

🔁

DDI and induction contextNevirapine and CYP-linked NNRTIs can shift the assay from concentration measurement to interaction interpretation.

Panel-aware HIV antiviral workflow design.Creative Proteomics connects parent-drug quantification, CYP / UGT metabolism, renal-excretion profiling, induction-aware DDI support, and multi-antiretroviral LC-MS/MS panels in one regimen-aware strategy.

HIV Antiviral Drug Index

Find the HIV Antiviral Compound Behind the Study

HIV antiviral projects often arrive as regimen questions rather than isolated compound questions. A zidovudine or dolutegravir study may point toward Phase II metabolism, efavirenz or rilpivirine may require CYP-aware MetID, nevirapine can shift the workflow into DDI / induction territory, while lamivudine, emtricitabine, and tenofovir place more weight on distribution, minimal metabolism, and excretion behavior. Use the index below to move from the compound name to the metabolism, DDI, or exposure workflow that actually drives the study.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only HIV antivirals matching all selected values.

10 entries · Page 1 of 4

Analytical Pain Points

What Drives Assay Failure in HIV Antiviral Studies?

HIV antiviral studies can fail when all antiretrovirals are forced into a single “antiviral concentration” workflow. This page includes NRTIs with limited metabolism, renal-excretion-dominant compounds, CYP-metabolized NNRTIs, induction-related DDI cases, and UGT-cleared integrase inhibitors. Each group can require a different analytical route even inside the same HIV antiviral library page.

Multi-Drug Regimens Need Panel-Aware Method Design

HIV antiviral research often involves more than one compound. A panel may include NRTIs, NNRTIs, integrase inhibitors, renal-excretion-dominant analytes, CYP substrates, UGT-cleared compounds, or induction-related DDI cases.

Our responseCustom LC-MS/MS antiretroviral panels with analyte-specific extraction, chromatographic selectivity, internal standard planning, MRM transitions, matrix-matched calibration, and dilution integrity.

Custom Drug Panels →

NRTIs with Minimal Metabolism Still Need Exposure-Ready Bioanalysis

Lamivudine, emtricitabine, and tenofovir are not primarily MetID-driven entries in this tag set. The key issue is often parent-drug exposure, distribution, minimal-metabolism interpretation, and renal-excretion-aware profiling.

Our responseIn vivo sample workflows around parent-drug concentration, matrix selection, concentration-window planning, distribution analysis, and excretion-focused interpretation.

LC-MS/MS Quantification →

CYP-Metabolized NNRTIs Require Phase I and DDI-Aware Workflows

Efavirenz, nevirapine, and rilpivirine introduce CYP-linked metabolism. Nevirapine also creates induction and DDI relevance, so a parent-only assay can miss the interaction question that determines study design.

Our responseCYP2B6 / CYP3A4-aware metabolism studies, microsome / hepatocyte workflows, MetID, parent-metabolite interpretation, and induction- or DDI-focused bioanalysis.

DDI Support →

UGT-Cleared Integrase Inhibitors Need Phase II Readout Control

Dolutegravir and raltegravir bring UGT-related Phase II metabolism into the workflow. If the method is designed only for parent-drug signal, glucuronidation-related interpretation may be under-supported.

Our responseUGT / Phase II workflows connecting parent-drug quantification, MetID, microsome / hepatocyte model analysis, and glucuronidation-aware interpretation.

MetID →

Regimen Context Can Turn Bioanalysis into DDI Interpretation

CYP substrates, enzyme induction, renal excretion, and panel co-quantification can all affect how exposure data are interpreted. Nevirapine-related induction and CYP-linked NNRTI metabolism make this especially important.

Our responseAlign analyte selection, study model, enzyme or DDI question, sample matrix, and reporting format so LC-MS/MS data support the regimen-level research objective.

Drug–Drug Interaction Support →

Focused Service Paths

Four Practical Routes for HIV Antiviral Studies

Instead of treating HIV antivirals as one generic antiviral group, the analytical route should be selected according to the study objective: parent-drug exposure, regimen panel development, renal distribution / excretion, CYP metabolism, UGT metabolism, DDI / induction support, or MetID.

Multi-Antiretroviral Panel Bioanalysis

For studies involving several HIV antivirals, regimen-context exposure, or simultaneous quantification of multiple antiretroviral classes.

NRTI / NNRTI / integrase inhibitor panels
Multi-drug exposure studies
Parent-drug co-quantification
Comparative antiviral exposure workflows

Custom Multi-Analyte Drug Panels →

Parent-Drug Exposure, Distribution, and Excretion Profiling

For compounds where parent-drug exposure, distribution, minimal metabolism, or renal excretion defines the DMPK question.

Lamivudine and emtricitabine distribution workflows
Tenofovir distribution and excretion profiling
In vivo sample analysis
Concentration-window planning

LC-MS/MS Drug Quantification →

CYP / UGT Metabolism and MetID Support

For studies where Phase I or Phase II metabolism, parent-metabolite interpretation, or enzyme-linked transformation defines the analytical workflow.

Efavirenz CYP2B6 / CYP3A4 metabolism
Rilpivirine CYP3A4 MetID
Zidovudine UGT2B7-related Phase II metabolism
Dolutegravir and raltegravir UGT-linked workflows

Metabolite Identification →

DDI and Induction-Focused HIV Antiviral Workflows

For studies where CYP metabolism, enzyme induction, or regimen-level interaction interpretation is central.

Nevirapine induction-related studies
CYP3A4 / CYP2B6-linked DDI context
Parent-metabolite interaction interpretation
Multi-drug regimen exposure analysis

Drug–Drug Interaction Support →

Project Inquiry

Need Support for a Novel or Unlisted HIV Antiviral?

If you are working with an NRTI, NNRTI, integrase inhibitor, boosted regimen component, renal-excretion-focused compound, CYP substrate, UGT-cleared drug, induction-related molecule, or a complex multi-antiretroviral panel, a standard parent-only LC-MS/MS method may not answer the study question.

Creative Proteomics develops custom LC-MS/MS and DMPK workflows by defining the regimen context, analyte list, enzyme route, DDI relevance, matrix type, expected concentration range, Phase I / Phase II metabolism needs, renal distribution or excretion objective, and panel compatibility before method development begins.

Target HIV antiviral

Regimen or panel context

CYP / UGT concern

DDI or induction question

MetID need

Distribution / excretion focus